Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib plus icotinib as first-line therapy in EGFR-mutated advanced NSCLC
ChiCTR2200060151Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib and icotinib in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: Progression-free survival. Started Mar 2022; status: recruiting.
02
Drugs
furmonertinibicotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200060151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060151.